What We Do
Transformative Therapies for Autoimmune Disease
Translating the biology of regulatory T cells into transformational medicines for patients.
The Abata Approach
A New Era: Treg Cell Therapy
Our targeted, autologous Treg cell therapies for progressive multiple sclerosis and other serious autoimmune diseases stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in affected tissues.
Who We Are
A team committed to groundbreaking science and patients
We are industry experts and scientific pioneers working together to bring an entirely new approach to the treatment of autoimmune disease.
Join Us
We welcome Monday mornings
We’re pushing the frontiers of science together, and we take joy in our work. We value people and believe in limitless possibilities, the power of diversity and the importance of kindness.
Press Release
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
First open IND for Abata’s best-in-class autologous T cell receptor (TCR)-Treg cell therapy platform for autoimmune disease
Expected initiation of first-in-human Phase 1 study in patients by end of year